BAHRI UNIVERSITY

Faculty of Medicine
Department of Microbiology

The relationship between Helicobacter pylori infection and Hyperemesis Gravidarum at Dongola Maternity Hospital, Northern State, Sudan,2026.

Thesis submitted for the fulfillment of PhD degree requirements in medical laboratory science (Microbiology)

By:

Wisal Salih Mohamed Saleh

Supervised by:

Prof. Saada Mohamed Nour, MSc, PhD (Medical microbiology)

Contents

Chapter one
Introduction
- 1.1 Introduction & background
- 1.2 Problem statement
- 1.3 Justification
- 1.4 Literature review
- 1.5 Objective
  - 1.5.1 General objective
  - 1.5.2 Specific objective

Chapter two
Methodology
- 2.1 Research period.
- 2.2 Study design
- 2.3 Study setting
- 2.4 Study population
  - 2.4.1 Inclusion criteria
- 2.5 Sample size
- 2.6 Sample collection place & time
- 2.7 Sampling technique
- 2.8 Data management & analysis
- 2.9 Ethical considerations & study

Chapter Three
Work Plan
- 3.1 Work plan (pregnant women)
  - 3.1.1 Collection sample Period
  - 3.1.2 Analysis Period
  - 3.1.3 Result Period
- 3.2 Budget
- 3.3 References

Chapter 1
Introduction

1.1 Background

Does Helicobacter pylori cause nausea & vomiting in pregnancy?

Hyperemesis gravid arum (HG) is a rare disorder characterized by severe nausea and vomiting? Hyperemesis gravid arum (HG) is an intractable form of nausea and vomiting affecting approximately 0.3–2 % of all pregnancies (1). HG is associated with maternal and perinatal morbidity, often requiring hospitalization and medical treatment to avoid life-threatening complications (2). Little is known about the etiology of HG, but a variety of mechanisms related to endocrine and immunologic factors, gastrointestinal conditions and metabolic enzymes have been proposed as possible underlying causes (3). Helicobacter pylori has been recognized to play a role in diseases of the gastrointestinal tract (4). It has been hypothesized that H. pylori may increase the risk of HG, to examine the association between H. pylori and HG, we conducted an updated meta-analysis. Pylori infection may increase the risk of HG, which might be explained by physiological changes in pregnancy and the virulence of the bacterium. First, gastric emptying and intestinal transit time may be prolonged during pregnancy due to elevated serum concentrations of steroid hormones and their relaxant effects on gastrointestinal smooth muscle (6). Second, it has been assumed that pregnancy increases women's susceptibility to infections due to some form of immune depression in the mother to allow for the survival of the fetal semi allograft (7), and latent infections might be reactivated in pregnancy (8). Hypothetically, decreased gastrointestinal motility and a depressed immune defense during pregnancy could result in the manifestation of a subclinical H. pylori infection, which in turn irritates the gastrointestinal tract. Finally, the inflammatory response to H. pylori might be determined by the virulence of the infecting strain and the human host (5). Moreover, it is interesting that antibiotics have relieved symptoms of nausea and vomiting in H. pylori-positive HG patients (9-10).

1.2 Problem Statement

It is known that the Symptoms of Helicobacter Pylori are the same as the signs of Hyperemesis Gravid arum. Therefore, it is somewhat of a complicated procedure to distinguish them from each other. The purpose of this scientific writing & research is to distinguish whether Helicobacter Pylori induces and increases the signs of Hyperemesis Gravid arum or if there is no connection between the two topics.

1.3 Justification

1. Symptoms of H. Pylori infections can be similar to those of hyperemesis gravid arum. Comparisons may be useful for a differential diagnosis.
2. Both are associated with nausea and vomiting.
3. Both cause problems such as a general feeling of discomfort in the stomach.
4. In both cases of hyperemesis gravid arum and H. pylori, drugs that may lessen nausea and vomiting can be prescribed.

1.4 Literature Review

Morning sickness is one of the typical symptoms of early pregnancy. It involves nausea and/or vomiting during the first few months of pregnancy. The name is somewhat misleading since nausea can actually set in at any time of the day. For many pregnant women, this symptom appears during the first trimester, and it generally resolves by around the 12th or 14th week. Some, however, suffer from an extreme form of morning sickness that lasts throughout the duration of the pregnancy. According to the National Health Service (UK, as many as 79-80% of pregnant women experience nausea and vomiting. An estimated 1.5% of pregnant women suffer from a severe form of morning sickness known as hyperemesis gravid arum. Accurate statistics are hard to obtain because not all such women necessarily seek or receive a formal diagnosis and treatment for this condition.

What Is Hyperemesis Gravid arum?

Some women suffer from a very severe form of morning sickness. Typically, this involves extreme nausea and excessive vomiting. The food that the woman does manage to eat may be vomited out soon after. As a result, the pregnant mother's body does not get the nutrition it needs both for its own maintenance as well as in order to support the development of the fetus.

This condition is generally severe enough to lead to significant weight loss, dehydration and electrolyte imbalance. It may leave the woman weak and unable to stand without feeling dizzy. Hence, she may become incapable of carrying out routine tasks by herself. This condition can last throughout the duration of pregnancy and can be so acute that the woman might require hospitalization. Although there is no cure for it, patients can tide over the symptoms with adequate rest, medications and support. This condition is transient and resolves when the pregnancy ends.

What Causes Hyperemesis Gravid arum?

It is unclear why some women suffer from extreme morning sickness whereas others do not. It is believed that hormonal changes associated with pregnancy might be responsible for giving rise to this condition. Specifically, the elevated quantities of estrogen and the pregnancy hormone called human chorionic gonadotropin have been blamed for this condition. It may also have to do with genetics to a certain extent.

The list below covers some risk factors that appear be relevant to this condition.
Some studies have found a correlation between hyperemesis gravid arum and infection with the bacterium Helicobacter pylori.

- The risk of suffering from hyperemesis gravid arum is higher in instances where the fetus is female.
- Women who have had multiple pregnancies are more likely to develop this condition.
- First-time mothers are also at risk.
- Those who are pregnant with more than one fetus are at risk as well.

What are the signs of hyperemesis gravid arum?

The symptoms of hyperemesis gravid arum tend to manifest sometime between the 4th and 6th weeks of pregnancy. They can range from moderate to debilitating in severity. It has also been noticed that some women with this condition develop transient hyperthyroidism. This means that they exhibit the signs of overactive thyroid function but that it lasts only as long as the pregnancy does and resolves soon after on its own. A more detailed list of symptoms associated with hyperemesis gravid arum are:

1. Severe nausea and vomiting. The vomiting may be triggered by strong smells.
2. Inability to keep food down after eating or fluids after drinking.
3. Developing aversion to certain foods.
4. Headaches, Loss of appetite, dehydration, Severe fatigue,
5. Reduced frequency and quantity of urine, Dizziness, Weight loss, acidosis as a result of malnutrition Electrolyte imbalance such as hypokalemia (abnormally low levels of potassium in the blood), elevated heart rate Blood in vomit, and fainting.

What Are Some Severe Outcomes Associated With Hyperemesis Gravidarum?
There can be a whole host of critical complications as a result of untreated hyperemesis gravid arum. This condition poses grave risks to the health of both the mother and the fetus. As a result, there can be severe pregnancy complications as well. In fact, in severe instances, the fetus could actually die.

How Is It Diagnosed?
Severe nausea, vomiting and the inability to tolerate ingested solids and fluids are the classic signs of this condition. Tests may be required to establish the extent of malnourishment and electrolyte disturbance, As well as any adverse effects on fetal development. There is no specific positive finding that definitively indicates hyperemesis gravid arum. Instead, depending on the symptoms displayed, the doctor may need first to rule out a variety of other possibilities. Some tests that can help to establish the diagnosis are:

1. Physical examination. The woman may have lost upwards of 5% of her pre-pregnancy body weight
2. Medical history
3. Blood tests to check for electrolyte disturbance, acidosis or alkalosis, for example
4. Urine tests help to confirm hyperemesis in case of relevant findings such as low water concentration and the presence of ketone bodies in the urine
5. Stool, serum, urea breath test for detection of H. Pylori infection

What Can Be Done For Relief?
The treatment of hyperemesis gravid arum is chiefly based on your symptoms and the way it is affecting your health. It is estimated that around 5% of females require care in a hospital setting. Other recommendations are as the following:

Lifestyle changes–Try having frequent smaller meals instead of fewer large ones. Consume plenty of fluids, sip by sip, preferably using a straw. In case hot foods trigger nausea, try cold foods. Doctors may also recommend nutritional supplements and electrolyte-replacement sports drinks in order to manage dehydration and your nutritional needs.
Stress Management–Get enough sleep and keep stress at bay by learning methods to manage stress.
Vitamin B supplements-Thiamine, or vitamin B1, is usually prescribed to ease vomiting. The prescribed dosage is 1.5 milligrams per day.
Ginger supplements-Ginger intake in small doses can help females with hyperemesis gravid arum. It can be consumed in various forms such as lollipops, tea, candies, supplements, etc. It is advised to take around 1 to 1.5 grams of ginger per day.
Medications– Anti-emetic drugs (drugs that help in reducing vomiting) are prescribed. These can be administered in the form of shots, pills, suppositories or by intravenous route (through a vein in your arm). In some cases, steroids are administered intravenously.
IV fluids- In case of dehydration, vitamins, and electrolytes are usually administered Intravenously, along with normal saline. Hyperemesis gravid arum cannot be prevented. However, the severity might be reduced a bit by taking multivitamins before conceiving and by preventing unhealthy weight gain during pregnancy.
Maintain a healthy pregnancy weight-being overweight can increase your risk of having hyperemesis gravid arum. Drink plenty of fluids in order to keep yourself from dehydration. You should drink slowly and use a straw to sip if possible.
Take vitamin supplements before and during pregnancy. Consult your doctor to know more about the required dosage for you.
Don't consume larger and fewer meals- divide your food into numerous small meals(11).

What is Helicobacter pylori?
Helicobacter pylori (H. pylori) is a common microaerophilic bacterium known to obstinately inhabit the human stomach mucous layer, affecting about half the world's population [12–14]. The pathogen is known to be present in the mucus, on the surface of the stomach lining, and its presence causes chronic inflammation, which remains a major cause of prolonged gastritis. Also, H. pylori has been identified to increase the risk of developing gastric adenocarcinoma [15]. Apart from gastrointestinal tract (GIT) related diseases such as gastro esophageal reflux disease, gastric ulcer and duodenal ulcer, infection with H. pylori has also been linked to some other diseases such as iron deficiency anemia [16, 17], immune thrombocytopenia (ITP) [16, 18], cardiovascular diseases [19, 20], hepatobiliary diseases [21, 22], diabetes mellitus [23], allergies, and asthma [24].

There is no certainty in the mode of transmission for H. pylori infection; however, various epidemiological studies have made several claims in this regard. The primary means of spread of the disease has been linked to transmission from one individual to another and is usually higher when occurring within a family [25–26]. The spread from person-to-person has been identified as the most likely and could be by oral-oral, gastro-oral or fecal-oral [27]. In this regard, the practice of good hygiene and improved living conditions becomes an essential factor in reducing the rate of transmission of the infection [28]. The prevalence of infection from H. pylori varies geographically, with the developing world carrying the higher burden [29]. Infection in peptic ulcer disease (PUDs) patients ranges from almost 25% in countries of the industrialized world and is anticipated to be around 90% in underdeveloped countries [30, 31]. The prevalence across countries in the West African region is generally high, with variations existing from country to country. The reportedly high prevalence observed in Africa (79.1%) and Asia (54.7%) as compared to lower prevalence found in other geographic locations such as Northern America (37.1%) and Oceania (24.4%) [17] has been found not to correlate with the rather low occurrence of gastric cancer [32, 30]. This situation has been described as the "Asian and African enigmas". These so-called "enigmas" have been explained by several factors, including host genetic and immune response, different tumor-inducing potential of specific strains of H. pylori, as well as environmental factors [33, 34]. It is imperative to mention that an individual who is infected with H. pylori faces a strenuous task of getting rid of the bacterium and hence disease eradication, a situation that is largely attributed to the ever-increasing antibiotic resistance [35]. In the near future, the problems associated with H. pylori eradication are feared to increase, looking at the current rising infection rates and gastroduodenal pathological outcomes. It is estimated that about 15% of infected individuals have an increased tendency to develop peptic ulcers [36], while a rate of 1–3% is found to have a greater propensity to develop gastric malignancy in their lifetime [37, 38]. With the changing epidemiology of infection from this organism, the pattern of other related diseases also keeps changing.

Influence of Host and H. pylori Genetic Factors on Infection

The distribution of H. pylori infection and the related pathology are mainly affected by host genetics and H. pylori virulence factors. In the progression of gastroduodenal diseases such as gastric cancer (GC), there seems to be an increased risk of development resulting from polymorphisms in several virulence genes. H. pylori genetic diversity is observed to be widespread and demonstrated in the disease outcomes of various strains, infection, and pathogen interaction with their human host. Although not clearly described, the level of genetic multiplicity is considered an element for adaptation of H. pylori in the stomach of the host and the clinical outcomes of the infection [39]. High-throughput sequencing revealed the diverse nature of the H. pylori genome [40], and variability in bacterial gens was used to establish a robust phytogeography distinction, a marker for human migrations [41, 42]. Human genetic polymorphisms also complement the geographical distribution of H. pylori and the clinical consequences. For example, persons carrying genetic variation in the pro-inflammatory interleukin-1-beta (IL-1b) and IL-1 receptor adversary genes are two to three times more likely to develop GC

[43]. Similarly, polymorphic tumor necrosis factor (TNF)-α as well as IL-16 genes were found to favor GC development during H. pylori infection [44, 45].

Environmental Factors in Helicobacter pylori Infection

Several factors have been reported to promote H. pylori infection and associated gastroduodenal diseases. Smoking, excessive alcohol intake, exposure to high levels of carcinogens, and diet are proven to be significantly involved in the pathogenesis of gastroduodenal diseases, including gastric cancer (GC) [46, 47]. Individuals with higher intake of refined carbohydrates, pickled, salted, or smoked foods, and dried fish and meat are at higher risk of developing GC than those who consume foods with higher amounts of fiber, fresh vegetables, and fruits [48]. Antioxidant properties of micronutrients contained in foods with high amounts of fiber and fresh fruits and vegetables are capable of lowering the risk of GC development by exerting a positive effect on the mucosa of the gastrointestinal tract. They can also adversely affect the mucosal protective mechanisms of the GI tract and increase the risk of H. pylori infection [49]. While the relation to the increase in infection may be due to antioxidant reduction or gastroduodenal immune system defense mechanisms, the adverse effect on mucosal protective mechanisms can be attributed to an increase in the production of gastric acid coupled with a reduction in the production of bicarbonate [50]. Studies have shown that smoking inhibits epithelial cell renewal, resulting in the alteration of mucosal cell proliferation.

This exposes the gastrointestinal tract to various aggressive factors, leading to an increased likelihood of the induction of cell apoptosis during ulceration and ulcer healing [51, 52].

Pathogenesis of Infection and Clinical Outcomes

Besides environmental and genetic factors, there are other important characteristics of H. pylori, such as the ability to enter, replicate, and persist in a host, which have been linked to the pathogenesis of gastroduodenal diseases [53, 54]. These factors come into play after the individual is exposed to the organism. When H. pylori first enters the host stomach, it is faced with the task of surviving the hostile acidic condition of a gastric acid bath, where pH could be as low as 1.5. The organism utilizes its urease activity to break down urea into ammonium ions and carbon dioxide. Once in the stomach, H. pylori resides on the epithelial surface. Movement into the mucosal lining is flagella-mediated, after which specific interactions between host cell receptors and bacterial adhesions follow. By these interactions, the bacterium latches onto the gastric epithelium and survives a possible displacement by the forces generated from the passing of food down the digestive tract. H. pylori possesses several strain-specific virulent genes aside from the typical virulence factors such as urease (UreA) and outer membrane protein (OMP) [55].

What are the symptoms of H. pylori infection?
Most people with H. pylori never have symptoms. But the bacteria can damage the inner protective lining of the stomach and cause other diseases, like a peptic ulcer. Symptoms of a peptic ulcer from H. pylori include: dull or burning stomach pain (especially when you have an empty stomach), bloating, nausea, unexplained weight loss, vomiting, burping, and poor appetite. While rare, stomach cancer is also a risk for people with H. pylori.

Stomach cancer symptoms include:
Nausea and vomiting, dehydration, poor appetite, unexplained weight loss, blood in the stool, feeling full early during a meal, discomfort or swelling in the abdomen, stomach pain, fatigue or weakness.
However, many of the symptoms of stomach cancer, peptic ulcers, and other diseases associated with H. pylori can be caused by other conditions. If you experience any symptoms that concern you, talk to a doctor. You should also seek medical attention immediately if you experience:
Difficulty swallowing, Anemia, Blood in the stool, Black-colored stools, vomiting blood.

Diagnosis
Several tests and procedures are used to determine whether you have an H. pylori infection. Testing is important for detecting H. pylori and should also be performed after treatment to make sure that the infection has been successfully eliminated.
Stool tests: The most common stool test to detect H. pylori is called a stool antigen test that looks for foreign proteins (antigens) associated with H. pylori infection in your stool.
Antibiotics and acid-suppressing drugs known as proton pump inhibitors (PPIs) and bismuth subsalicylate (Pepto-Bismol) can interfere with the accuracy of these tests. If you were previously diagnosed with and treated for H. pylori, your doctor will generally wait at least four weeks after you complete your antibiotic treatment to test your stool. If you are taking a PPI, your doctor will ask you to stop taking PPI medications for one or two weeks before the test.
A laboratory test called a stool **polymerase chain reaction (PCR)** test can detect H. pylori infection in your stool and mutations that may be resistant to antibiotics used to treat it. This test is more expensive and may not be available at all medical centers.
Breath test-During a breath test, you swallow a pill, liquid or pudding that contains tagged carbon molecules. If you have an H. pylori infection, the solution **breaks** down in your stomach **and releases carbon**. Your body absorbs the carbon and expels it when you exhale. You exhale into a bag, and your doctor uses a special device to detect the carbon molecules. As with stool tests, PPIs, bismuth subsalicylate (Pepto-Bismol),and antibiotics can interfere with the accuracy of this test. If you are taking a PPI, your doctor will ask you to stop taking the PPI for one or two weeks before the test. If you were previously diagnosed with and treated for H. pylori, your doctor will generally wait at least four weeks after you complete your antibiotic treatment to perform the breath test.

Scope test-You'll be sedated for this test, known as an upper endoscopy exam. This instrument lets your doctor view any irregularities in your upper digestive tract and remove tissue samples (biopsies). These samples are analyzed for H. pylori infection. This test is done to investigate symptoms that may be caused by other conditions, such as a gastric ulcer or gastritis, that may be due to H. pylori.
This test isn't always recommended solely to diagnose an H. pylori infection because it's more invasive than a breath or stool test.

Treatment
H. pylori infections are usually treated with at least two different antibiotics at once, to help prevent the bacteria from developing a resistance to one particular antibiotic. also will prescribe or recommend an acid-suppressing drug, to help your stomach lining heal. Drugs that can suppress acid include:
Proton pump inhibitors (PPIs): These drugs stop acid from being produced in the stomach. Some examples of PPIs are omeprazole (Prilosec), esomeprazole (Nexium), lansoprazole (Prefaced) and pantoprazole (Protonic). Histamine (H-2) blockers. These medications block a substance called histamine, which triggers acid production. One example is cimetidine (Tagamet HB).
Bismuth subsalicylate-More commonly known by the brand name Pepto-Bismol works by coating the ulcer and protecting it from stomach acid. may recommend that you undergo testing for H. pylori at least four weeks after your treatment. If the tests show the treatment was unsuccessful, you may undergo another round of treatment with a different combination of antibiotic medications.

1.5 Objective

1.5.1 General objective

To investigate the relationship between hyperemesis gravid arum and Helicobacter pylori infection.

1.5.2 Specific Objective

1. To determine the prevalence of Helicobacter pylori infection among pregnant women, including Asymptomatic women and those with hyperemesis gravid arum.
2. To investigate the clinical signs and symptoms of H. Pylori infection in pregnant women.
3. To assess the clinical signs and symptoms among pregnant women (symptomatic & Asymptomatic).

Chapter 2
Methodology

2.1 Research period from 2022 to 2026
2.2 Study Design
2.3 Study Setting
The Study for pregnant women will be conducted at Dongola Maternity Hospital, Northern State, Sudan, 2026.

2.4 Study Population
Enrolled 100 pregnant women with Hyperemesis Gravid arum.
2.4.1 Inclusion Criteria
The study included 100 Pregnant women during all trimesters. All of whom were attending Dongola Maternity Hospital, Northern State, Sudan.

2.5 Sample Size
The study sample size will be calculated using an appropriate sample size calculator.
Total study population: 100 participants
Confidence level : __ %
Margin of error : __ %
Population proportion : __ %

2.6 Sample collection place &time:
The study will be conducted at Dongola Maternity Hospital, Northern State, Sudan, in 2026.

2.7 Sample Technique
The presence of Helicobacter pylori (H. Pylori) antigen will be detected in stool sample collected from the study group.
The detection of H. pylori Antigen will be performed using Stool specimens collected from pregnant women during The 1st trimester and up to 9 months of pregnancy.
The presence of H. pylori antigens in stool specimens will be assessed using a rapid , one step H. pylori card test (on site H. pylori rapid test), which is a chromatographic immunoassay used to detect H. pylori infection. In the test-band region , monoclonal antibodies are used to pre-coat the membrane against H. pylori-antigens. The test involves a reaction between the stool sample and the colored conjugate, which consists of anti-H. pylori monoclonal antibodies bound to red polystyrene micro-spheres. The mixture is then transferred to the test strip through capillary action.
The colored particles migrate across the membrane and are captured by specific antibodies immobilized on the membrane. The appearance of a colored band in the test region indicates a positive result. The mixture continues to migrate across the membrane toward the antibodies immobilized in the control-band region. The appearance of red band in the control region indicates that the test has functioned properly and that there was adequate sample volume and proper flow.

Stool samples will be collected and tested according to the manufacturer's instructions provided with the test kit.
A negative result is indicated by the appearance of only one red band in the control region, with no band appearing in the test region.

2.8 Data Management & Analysis
The collected data will be organized, entered, and analyzed using appropriate statistical methods. The results will be presented in the form of tables and pie charts.

2.9 Ethical considerations
The study, including sample collection and testing, will be conducted after obtaining all necessary ethical approvals and informed consent from the participants. The study will be carried out at Dongola Maternity Hospital, Northern State,Sudan,2026.While maintaining the confidentiality and privacy of all participants.

Chapter 3
Work Plan

3.1 Research Work Plan (Pregnant Women)

Research Stages	First Trimester	Second Trimester	Third Trimester
Topic Selection			
Data Collection			
Literature Review			
Research Methodology Plan			
Research Techniques			
Data Analysis and Interpretation			
Findings and Recommendations			
Final Research Project			

3.1.1 Sample Collection Period
September-October 2026
3.1.2 Analysis Period
September-October 2026
3.1.3 Results Period
September-October 2026
Excepted Results
Exposure to H. pylori appears to be associated with an increased risk of hyperemesis gravid arum. The residual heterogeneity may have several explanations. Given the high prevalence of H. pylori, heterogeneity may also be attributed to differences in the methods used to ascertain infection. Stool Antigen tests were used, and their positive and negative predictive values vary depending on the prevalence of H. pylori in the populations, which is known to vary from one country to another and among different subpopulations within the same country.

3.2 Budget

Items	Breakdown	Cost (SDG)
Preparation of the Questionnaire		
Data Collection		
Transportation		
Data Processing and Analysis		
Reports Writing and Printing Out		
Total		

3.3 References

1. Eliakim R, Abulafia O, Sherer DM. Hyperemesis gravidarum: A current review. American Journal of Perinatology. 2000; 17: 207– 218.
2. Ismail SK, Kenny L. Review on hyperemesis gravidarum. Best Practice & Research Clinical Gastroenterology. 2007; 21: 755–769.
3. Verberg MF, Gillott DJ, Al-Fardan N, Grudzinskas JG. Hyperemesis gravidarum: Aliterature review. Human Reproduction Update. 2005; 11: 527– 539.
4. Suerbaum S, Michetti P. Helicobacter pylori infection. New England Journal of Medicine . 2002; 347: 1175– 1184.
5. Robinson K, Argent RH, Atherton JC. The inflammatory and immune response to Helicobacter pylori infection. Best Practice & Research Clinical Gastroenterology. 2007; 21: 237– 259.
6. Zimmermann EM, Christman GM. Approach to gastrointestinal and liver diseases in the female patient. In: Yamada T, editor. Textbook of Gastroenterology. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2003. p. 1033– 1055.
7. Manyonda IT. The immune system. In: Chamberlain G, Pipkin FB, editors. Clinical Physiology in Obstetrics. 3rd ed. Oxford: Blackwell Science Ltd;1998. p. 129–162.
8. Stagno S, Reynolds DW, Huang ES, Thames SD, Mith RJ, Alford CA. Congenital cytomegalovirus infection. New England Journal of Medicine. 1977; 296: 1254–1258.
9. Strachan BK, Jokhi RP, Filshie GM. Persistent hyperemesis gravidarum and Helicobacter pylori. Journal of Obestetrics and Gynaecology. 2000; 20: 427.
10. EL Younis CM, Abulafia O, Sherer DM. Rapid marked response of severe hyperemesis gravidarum to oral erythromycin. American Journal of Perinatol. 1998; 15: 533– 534.
11. https://www.womenshealth.gov/pregnancy/yourepregnant-now-what/pregnancy-complications
12. https://www.webmd.com/baby/what-is-hyperemesisgravidarum#1
13. https://emedicine.medscape.com/article/254751-overview
14. https://my.clevelandclinic.org/health/diseases/12232hyperemesis-gravidarum-severe-nausea-vomiting-duringpregnancy
15. https://www.healthline.com/health/hyperemesisgravidarum#diagnosis
16. http://americanpregnancy.org/pregnancycomplications/hyperemesis-gravidarum/
17. Tonkic A, Tonkic M, Lehours P, Mégraud F. Epidemiology and diagnosis of Helicobacter pylori infection, Helicobacter.2012;17:1-8.
18. P. Malfertheiner, F. Megraud, C. A. O'Morain et al., "Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report," Gut, vol. 66, no. 1, pp. 6–30, 2017. View at: Publisher Site | Google Scholar.
19. H. M. Mitchell, Epidemiology of Infection, vol. 2, ASM Press, Washington, DC, 2001.

20. S. Suerbaum and P. Michetti, "Helicobacter pylori infection," New England Journal of Medicine, vol. 347, no. 15, pp. 1175–1186, 2002. View at: Publisher Site | Google Scholar M. Banić, F. Franceschi, Z. Babić, and A. Gasbarrini, "Extra-gastric manifestations of Helicobacter pylori infection," Helicobacter, vol. 17, pp. 49– 55, 2012. View at: Publisher Site | Google Scholar.
21. W. Xia, X. Zhang, W. Wang, C. Sun, and L. Wu, "Survey of anaemia and Helicobacter pylori infection in adolescent girls in Suihua, China and enhancement of iron intervention effects by H. pylori eradication," British Journal of Nutrition, vol. 108, no. 2, pp. 357–362, 2012. View at: Publisher Site | Google Scholar
22. K. Kohda, T. Kuga, K. Kogawa, et al., "Effect of Helicobacter pylori eradication on platelet recovery in Japanese patients with chronic idiopathic thrombocytopenic purpura and secondary autoimmune thrombocytopenic purpura," British Journal of Haematology, vol. 118, no. 2, pp. 584–588, 2002. View at: Publisher Site | Google Scholar
23. M. Rogha, M. Nikvarz, Z. Pourmoghaddas, K. Shirneshan, D. Dadkhah, and M. Pourmoghaddas, "Is Helicobacter pylori infection a risk factor for coronary heart disease?" ARYA Atherosclerosis, vol. 8, no. 1, p. 5, 2012. View at: Google Scholar.
24. F. Franceschi, G. Niccoli, G. Ferrante, et al., "CagA antigen of Helicobacter pylori and coronary instability: Insigh from a clinico-pathological study and a meta-analysis of 4241 cases," Atherosclerosis, vol. 202, no. 2, pp. 535–542, 2009. View at: Publisher Site | Google Scholar
25. G. Isaeva, E. Abuzarova, I. Valeeva, O. Pozdeev, and E. Murav'eva, "Helicobacter pylori in patients with disorders of hepatobiliary system," Zhurnal Mikrobiologii, Epidemiologii Immunobiologii, vol. 2, pp. 96–101, 2009. View at: Google Scholar
26. T. Pirouz, L. Zounubi, H. Keivani, N. Rakhshani, and M. Hormazdi, "Detection of Helicobacter pylori in paraffin-embedded specimens from patients with chronic liver diseases, using the amplification method," Digestive Diseases and Sciences, vol. 54, no. 7, pp. 1456–1459, 2009. View at: Publisher Site | Google Scholar
27. D. Ortiz-Princz, G. Daoud, A. Salgado-Sabel, and M. Cavazza, "Helicobacter pylori infection in children: Should it be carefully assessed?" European Review for Medical Pharmacological Sciences, vol. 20, no. 9, pp. 1798–1813, 2016. View at: Google Scholar
28. D. Jaspersen, M. Kulig, J. Labenz, et al., "Prevalence of extraoesophageal manifestations in gastro-oesophageal reflux disease: An analysis based on the ProGERD study," Alimentary Pharmacology and Therapeutics, vol. 17, no. 12, pp. 1515– 1520, 2003. View at: Publisher Site | Google Scholar
29. A. Seck, M. Mbengue, A. Gassama-Sow, L. Diouf, M. M. Ka, and C. S.-B. Boye, "Antibiotic susceptibility of Helicobacter pylori isolates in Dakar, Senegal," The Journal of Infection in Developing Countries, vol. 3, no. 2, pp. 137–140, 2009. View at: Publisher Site | Google Scholar
30. M. B. Adinortey, C. Ansah, C. A. Adinortey, A. S. Bockarie, M. T. Morna, and D. H. Amewowor, "Isolation of Helicobacter pylori from gastric biopsy of dyspeptic patients in Ghana and in vitro preliminary assessment of the effect of Dissotis

rotundifolia extract on its growth," Journal of Tropical Medicine, vol. 2018, pp. 1–6, 2018. View at: Publisher Site | Google Scholar
31. Y. Urita, T. Watanabe, N. Kawagoe et al., "Role of infected grandmothers in transmission of Helicobacter pylori to children in a Japanese rural town," Journal of Paediatrics and Child Health, vol. 49, no. 5, pp. 394–398, 2013.
32. A. Mentis, P. Lehours, and F. Mégraud, "Epidemiology and diagnosis of Helicobacter pylori infection," Helicobacter, vol. 20, pp. 1–7, 2015.
33. L. M. Brown, "Helicobacter pylori: Epidemiology and routes of transmission," Epidemiologic Reviews, vol. 22, no. 2, pp. 283–297, 2000.
34. K. L. Goh, W. K. Chan, S. Shiota, and Y. Yamaoka, "Epidemiology of Helicobacter pylori infection and public health implications," Helicobacter, vol. 16, pp. 1–9, 2011.
35. F. Vale and J. Vítor, "Transmission pathway of Helicobacter pylori: Does food play a role in rural and urban areas?" International Journal of Food Microbiology, vol. 138, nos. 1–2, pp. 1–12, 2010.
36. M. Go, "Natural history and epidemiology of Helicobacter pylori infection," Alimentary Pharmacology & Therapeutics, vol. 16, pp. 3–15, 2002.
37. R. Hunt, S. Xiao, F. Megraud et al., "Helicobacter pylori in developing countries: World Gastroenterology Organisation Global Guideline," Journal of Gastrointestinal and Liver Diseases, vol. 20, no. 3, pp. 299–304, 2011.
38. P. K. Bardhan, "Epidemiological features of Helicobacter pylori infection in developing countries," Clinical Infectious Diseases, vol. 25, no. 5, pp. 973–978, 1997.
39. M. Zamani, F. Ebrahimtabar, V. Zamani et al., "Systematic review with meta-analysis: The worldwide prevalence of Helicobacter pylori infection," Alimentary Pharmacology & Therapeutics, vol. 47, no. 7, pp. 868–876, 2018.
40. J. K. Hooi, W. Y. Lai, W. K. Ng et al., "Global prevalence of Helicobacter pylori infection: Systematic review and meta-analysis," Gastroenterology, vol. 153, no. 2, pp. 420–429, 2017.
41. C. Holcombe, "Helicobacter pylori: The African enigma," Gut, vol. 33, no. 4, pp. 429– 431, 1992.
42. K. Singh and U. C. Ghoshal, "Causal role of Helicobacter pylori infection in gastric cancer: An Asian enigma," World Journal of Gastroenterology, vol. 12, no. 9, p. 1346, 2006.
43. U. C. Ghoshal, R. Chaturvedi, and P. Correa, "The enigma of Helicobacter pylori infection and gastric cancer," Indian Journal of Gastroenterology, vol. 29, no. 3, pp. 95–100, 2010.
44. Y. Hu, Y. Zhu, and N.-H. Lu, "Novel and effective therapeutic regimens for Helicobacter pylori in an era of increasing antibiotic resistance," Frontiers in Cellular and Infection Microbiology, vol. 7, 2017.
45. E. Kuipers, J. Thijs, and H. Festen, "The prevalence of Helicobacter pylori in peptic ulcer disease," Alimentary Pharmacology & Therapeutics, vol. 9, pp. 59–69, 1995.
46. M. Gasparetto, M. Pescarin, and G. Guariso, "Helicobacter pylori eradication therapy: Current availabilities," ISRN Gastroenterology, vol. 2012, pp. 1–8, 2012.

47. L. Boyanova, "Helicobacter pylori resistance to antibiotics," Helicobacter pylori, vol. 201, 2011. Available at: Google Scholar.
48. M. Safavi, R. Sabourian, and A. Foroumadi, "Treatment of Helicobacter pylori infection: Current and future insights," World Journal of Clinical Cases, vol. 4, no. 1, p. 5, 2016. Available at: Google Scholar
49. V. Conteduca, D. Sansonno, G. Lauletta, S. Russi, G. Ingravallo, and F. H. Dammacco, "Pylori infection and gastric cancer: State of the art," International Journal of Oncology, vol. 42, no. 1, pp. 5–18, 2013. Available at: Publisher Site | Google Scholar
50. B. Zhao, J. Zhao, W.-F. Cheng, et al., "Efficacy of Helicobacter pylori eradication therapy on functional dyspepsia," Journal of Clinical Gastroenterology, vol. 48, no. 3, pp. 241– 247, 2014. Available at: Publisher Site | Google Scholar
51. S. Kabir, "Effect of Helicobacter pylori eradication on incidence of gastric cancer in human and animal models: Underlying biochemical and molecular events," Helicobacter, vol. 14, no. 3, pp. 159–171, 2009. Available at: Google Scholar
52. H. M. Malaty, D. G. Evans, D. J. Evans, and D. Y. Graham, "Helicobacter pylori in Hispanics: Comparison with Blacks and Whites of similar age and socioeconomic class," Gastroenterology, vol. 103, no. 3, pp. 813–816, 1992. Available at: Publisher Site | Google Scholar
53. H. M. Malaty, D. Y. Graham, W. A. Wattigney, S. R. Srinivasan, M. Osato, and G. S. Berenson, "Natural history of Helicobacter pylori infection in childhood: 12-year follow-up cohort study in a biracial community," Clinical Infectious Diseases, vol. 28, no. 2, pp. 279 - 282, 1999. Available at: Publisher Site | Google Scholar
54. B. A. Salih, "Helicobacter pylori infection in developing countries: The burden for how long?" Saudi Journal of Gastroenterology: Official Journal of the Saudi Gastroenterology Association, vol. 15, no. 3, p. 201, 2009. Available at: Google Scholar
55. M. A. Tkachenko, N. Z. Zhannat, L. V. Erman, et al., "Dramatic changes in the prevalence of Helicobacter pylori infection during childhood: A 10-year follow-up study in Russia," Journal of Pediatric Gastroenterology and Nutrition, vol. 45, no. 4, pp. 428–432, 2007. Available at: Publisher Site | Google Scholar
56. C. Malcolm, W. MacKay, A. Shepherd, and L. Weaver, "Helicobacter pylori in children is strongly associated with poverty," Scottish Medical Journal, vol. 49, no. 4, pp. 136–138, 2004. Available at: Publisher Site | Google Scholar
57. J. Thomas, A. Dale, and J. Bunn, "Early Helicobacter pylori colonisation: The association with growth faltering in The Gambia," Archives of Disease in Childhood, vol. 89, no. 12, pp. 1149–1154, 2004. Available at: Publisher Site | Google Scholar
58. P. Sullivan, J. Thomas, D. Wight, et al., "Helicobacter pylori in Gambian children with chronic diarrhoea and malnutrition," Archives of Disease in Childhood, vol. 65, no. 2, pp. 189–191, 1990. Available at: Publisher Site | Google Scholar
59. A. Olokoba, W. Gashau, S. Bwala, A. Adamu, and F. Salawu, "Helicobacter pylori infection in Nigerians with dyspepsia," Ghana Medical Journal, vol. 47, no. 2, pp. 79–81, 2013. Available at: Google Scholar